VA prepares for psychedelic therapies to treat veteran PTSD and depression

What it does

This bill creates a new Office of Novel Therapeutics within the Veterans Health Administration to prepare for and implement emerging mental health treatments—particularly psychedelic-assisted therapies under FDA review—for veterans with PTSD, depression, and other conditions. The office will develop clinical standards, training programs, implementation plans, and designate centers of excellence to ensure safe, coordinated rollout of these therapies across the VA system when approved.

Why we flagged it

The bill's core function is establishing organizational and clinical infrastructure within the VA to safely evaluate and implement emerging psychedelic-assisted and other novel therapies for veteran mental health conditions. It is a preparedness and governance measure, not a direct appropriation or treatment authorization.

What the text implies

• The bill does not authorize or approve any specific therapy; it creates the administrative apparatus to implement therapies once FDA-approved. This means the actual clinical rollout depends on separate FDA decisions and VA implementation decisions, creating a two-stage gate.
• The interagency coordination requirement (section 7396) with DEA, HHS, and FDA suggests potential scheduling/rescheduling of controlled substances (e.g., psilocybin, MDMA) may be anticipated; the bill does not assume these are already legal but prepares the VA to move quickly once they are.
• The 'effectiveness-implementation hybrid' research model (section 7393) may generate real-world evidence that influences FDA decisions or reimbursement policy beyond the VA, potentially affecting private-sector adoption of these therapies.
• Veteran Advisory Committee membership includes 'family members or caregivers,' expanding input beyond veterans themselves—a rare and potentially significant inclusion in VA governance that may set precedent for other VA programs.

Who it affects

Veterans gain access to potentially life-changing emerging treatments with centralized safety oversight, standardized training, and dedicated infrastructure. The bill prioritizes patient safety, veteran input, and evidence-based implementation over rushed or inconsistent deployment. No apparent cost to non-veteran taxpayers beyond normal VA operations.

Named in the bill

Veterans Health Administration, Department of Veterans Affairs, Food and Drug Administration, Centers for Medicare & Medicaid Services, Department of Defense, Drug Enforcement Administration, Office of Novel Therapeutics, Veteran Advisory Committee on Novel Therapeutics

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Mar 26, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 26, 2026 — Referred to Senate Committee on Veterans' Affairs · Congress.gov: “Read twice and referred to the Committee on Veterans' Affairs”
• Apr 29, 2026 — Hearing held · Congress.gov: “Committee on Veterans' Affairs. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $197,500 in lobbying spend. A filing names 13 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Tim Sheehy, the sponsor, reported $398,825 in PAC receipts in the 2026 cycle.

• Iraq and Afghanistan Veterans of America Inc — $120,000 on 1 filing
• Brainfutures — $40,000 on 1 filing
• Wounded Warrior Project — $30,000 on 1 filing
• Sana Health — $7,500 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.